Author(s)Healy BC, Glanz BI, Zurawski JD, Mazzola M, Chitnis T, Weiner HL. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta, glatiramer acetate. J Neurol Sci.
A new study found extensive alternative splicing of messenger RNA in the blood cells of untreated multiple sclerosis patients compared to healthy controls. The study, which showed that highly ...
(A) Bio-imaging analysis to evaluate the therapeutic effect of iPS-ML producing IFN-β on metastatic liver cancer. (B) Quantification of the image data shown in A. (C) Histological data indicating ...
Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an α 4 integrin antagonist, appeared to be safe ...
Treatment with interferon or with glatiramer acetate? This question arises for many patients who receive a diagnosis of multiple sclerosis (MS) for the first time. Until now, the choice between the ...
The use of interferon-beta (IFN-beta) by pregnant patients with multiple sclerosis poses no risk to an infant’s birth weight, length, or head circumference, according to a recent study. The use of ...
VirMAP for cancer: Characterization of the intratumoral virome in virally associated cancers and a resource for investigators. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results